Novel therapeutic approaches including intra-articular administration of inhibitors of key pain mediators such as NGF and TRPV-1 have yielded promising early results but are yet to be studied in the context of obesity. This evidence concerns the gene NGF and obesity due to melanocortin 4 receptor deficiency.